System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Milan Lukas is an expert in Gastroenterology at Charles University (Czechia). As of October 2026, ScienceLeadR ranks Milan Lukas in the top 1% of experts worldwide for Colitis, Inflammatory Bowel Diseases and Gastroenteritis. Milan Lukas has authored 317 publications, the most recent in 2026, and is an investigator in 32 clinical trials, 8 of them ongoing. SLR score: 1,573 (community average: 125). How the SLR is computed.

LeadR Profile

Milan Lukas Charles University Czechia
1 573 ScienceLeadR Reputation 1573

Unlock

Register Login
Network Map

Gastroenterology

Subspecialties: Hepatology - Medical Imaging - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2004 - 2026
Source: PubMed

Charles University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 317

Citations

Citations: 14 118 1st author: 17 Last author: 78 Unique author: 48

Main journals

Gastroenterologie a hepatologie 82
Gastroenterology 62
J Crohns Colitis 39
Inflamm Bowel Dis 13
Gastrointest Endosc 9

Best Journals

N Engl J Med 6
Lancet Gastroenterol Hepatol 5
Gastroenterology 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Long-term real-world effectiveness and safety of mirikizumab in ulcerative colitis: 52-Week results from an expanded international two-center retrospective cohort study.
PMID 42712747 — colitis, safety, pharmaceutical preparations, cohort studies, therapeutics, colitis, ulcerative		Ther Adv Gastroenterol20260
Mirikizumab in ulcerative colitis: real-world evidence from an international two-center retrospective cohort study.
PMID 41230020 — colitis, safety, adrenal cortex hormones, cohort studies, therapeutics, colitis, ulcerative		Therap Adv Gastroenterol20250
Sequencing JAK-inhibitors in ulcerative colitis: effectiveness and safety of switching within treatment class.
PMID 41183095 — colitis, safety, inflammatory bowel diseases, therapeutics, janus kinase inhibitors, steroids, colitis, ulcerative		J Crohns Colitis20250
Risk factors for difficult endoscopic bowel dilation of predominantly shorter and noninflammatory strictures among patients with inflammatory bowel disease: findings from inflammatory bowel disease tertiary centers in Poland and Czech Republic.
PMID 40044092 — constriction, pathologic, gastroenterology, multiple chronic conditions, endoscopy, inflammatory bowel diseases, risk factors, therapeutics, immunosuppression therapy, smoking		Gastrointest Endosc20250
Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn's Disease.
PMID 40971924 — ustekinumab, safety, crohn disease, biomarkers, maintenance, inflammatory bowel diseases, therapeutics, colitis, ulcerative		Inflamm Bowel Dis20250

Clinical Studies 32

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 22
Phase 2 6
Phase 2/Phase 3 3
N/A 1

By status:

Completed 18
Not yet recruiting 4
Recruiting 4
Active not recruiting 2
Terminated 2
Unknown 2

By type:

Interventional 31
Observational 1

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 1
multicentric5to9 0
multicentricup10 29

Main Topics

Cohort/Consortium Investigators 4

Ongoing Clinical Trials

8 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Efficacy and Safety of JNJ 78934804 in Participants With Moderately to Severely Active Crohn s Disease
2026-525922-39-00 — safety, crohn disease		Phase 3Not yet recruiting2026
Efficacy and Safety of JNJ 78934804 in Participants with Moderately to Severely Active Ulcerative Colitis
2026-525923-26-00 — colitis, safety, colitis, ulcerative		Phase 3Recruiting2026
A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn s disease
2025-521037-86-00 — safety, crohn disease, maintenance, immune system diseases, immune system		Phase 3Recruiting2026
A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative colitis
2025-521038-27-00 — colitis, safety, maintenance, immune system diseases, immune system, colitis, ulcerative		Phase 3Recruiting2026
A study of LY4268989 in participants with Moderately to Severely Active Ulcerative Colitis (EMERALD 3)
2025-524404-29-00 — colitis, safety, program development, therapeutics, colitis, ulcerative		Phase 2Not yet recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS